Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $17.10.

ROIV has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Monday, August 19th. Piper Sandler raised their target price on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, July 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, June 18th.

Institutional Trading of Roivant Sciences

Several hedge funds have recently added to or reduced their stakes in ROIV. Clearbridge Investments LLC increased its stake in Roivant Sciences by 51.3% during the 2nd quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company's stock valued at $19,666,000 after buying an additional 630,712 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in shares of Roivant Sciences by 318.8% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 158,300 shares of the company's stock valued at $1,674,000 after acquiring an additional 120,500 shares during the period. Cetera Investment Advisers raised its holdings in Roivant Sciences by 39.4% during the second quarter. Cetera Investment Advisers now owns 100,288 shares of the company's stock worth $1,060,000 after purchasing an additional 28,324 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Roivant Sciences by 40.1% in the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company's stock worth $6,840,000 after purchasing an additional 185,226 shares during the period. Finally, Quarry LP bought a new position in Roivant Sciences during the 2nd quarter valued at $53,000. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Up 1.7 %

Roivant Sciences stock traded up $0.21 during midday trading on Friday, hitting $12.23. The stock had a trading volume of 5,081,470 shares, compared to its average volume of 5,657,485. The company has a current ratio of 25.24, a quick ratio of 25.24 and a debt-to-equity ratio of 0.07. The business has a fifty day moving average price of $11.07 and a 200 day moving average price of $11.00. Roivant Sciences has a 12 month low of $8.24 and a 12 month high of $13.24. The stock has a market cap of $9.03 billion, a P/E ratio of 2.42 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 25.05% and a net margin of 3,484.86%. The business had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same period in the previous year, the business earned ($0.38) EPS. The business's quarterly revenue was up 155.1% on a year-over-year basis. Research analysts predict that Roivant Sciences will post -1.12 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.